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Background: The Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS) showed no benefit
in the reduction of major neonatal mortality/morbidity or neurodevelopment at 2 and 5 years of age. Using the
data from the randomized controlled trial and its follow-up, the aim of this study was to evaluate the association
between gestational ages at birth in children exposed to single versus multiple courses of antenatal corticosteroid
(ACS) therapy in utero and outcomes at 5 years of age.
Method: A total of 1719 children, with the breakdown into groupings of <30, 30–36, and ≥ 37 weeks gestation at
birth, contributed to the primary outcome: death or survival with a disability in one of the following domains:
neuromotor, neurosensory, and neurobehavioral/emotional disability and were included in this analysis.
Results: Gestational age at birth was strongly associated with the primary outcome, p < 0.001. Overall, the interaction
between ACS groups and gestational age at birth was not significant, p = 0.064. Specifically, in the 2 preterm categories,
there was no difference in the primary outcome between single vs. multiple ACS therapy. However, for infants
born ≥37 weeks gestation, there was a statistically significant increase in the risk of the primary outcome in multiple ACS
therapy, 48/213 (22.5%) compared to 38/249 (15.3%) in the single ACS therapy; OR = 1.69 [95% CI: 1.04, 2.77]; p = 0.037.
Conclusion: Preterm birth (<37 weeks gestation) remained the primary factor contributing to an adverse outcome
regardless of the number of courses of ACS therapy. Children born≥ 37 weeks and exposed to multiple ACS therapy may
have an increased risk of neurodevelopmental/neurosensory impairment by 5 years of age. To optimize outcomes for
infants/children, efforts in reducing the incidence of preterm birth should remain the primary focus in perinatal research.
Trial registration: This study has been registered at (identifier NCT00187382)
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The Multiple Courses of Antenatal Corticosteroids
for Preterm Birth Study (MACS) is an international,
multicenter, double-masked, randomized controlled
trial that compared multiple courses of antenatal
corticosteroids (ACS) given every 14 days to a single
course in women at increased risk for preterm birth [1].
The initial report found that infants born to women in the
multiple ACS group had similar composite mortality and
morbidity (severe respiratory distress syndrome, grade
III or IV intraventricular hemorrhage, periventricular
leukomalacia, bronchopulmonary dysplasia, or necrotizing
enterocolitis) as compared with those in the single course
group [1]. However, multiple courses of ACS reduced fetal
growth. At 18–24 months of age, there were no significant
differences in death or neurologic disability (cerebral palsy
or cognitive delay) in children born to women in the
multiple antenatal corticosteroids group compared to
the placebo group [2]. At 5 years of age, no significant
differences in the primary composite outcome of death
or neurodevelopmental disability were seen between
the two groups [3].
Using the data from the randomized controlled
trial and its follow-up, the aim of this study was to
perform a secondary analysis examining the association of
gestational age at birth on the comparison between single
and multiple courses of ACS therapy with respect to
outcomes at 5 years of age.
Methods
Initial study and 18–24 months and 5-year follow-up
Women were enrolled in the MACS if they were between
25 and 32 weeks of gestation, remained pregnant 14 to
21 days after an initial course of antenatal corticosteroid
therapy (either betamethasone or dexamethasone) therapy,
and continued to be viewed as at high risk of preterm
birth by their clinicians. Women were not eligible if
they had a contraindication to corticosteroid use,
needed chronic treatment with these drugs, demonstrated
evidence of chorioamnionitis, carried a fetus with a known
lethal congenital anomaly, had received an initial course
of prenatal corticosteroid therapy before 23 weeks of
gestation, or had participated previously in the MACS
trial. In multiple-fetus pregnancies, if a fetus was
thought to have died prior to 13 weeks, that fetus was not
considered part of the pregnancy for the purposes of
this study. Women assigned to the multiple courses
arm received two doses of 12 mg betamethasone
intramuscularly 24 hours apart; those assigned to the
single course arm received a similarly appearing placebo
injection. The study medication was given every two
weeks until 33 weeks of gestation or birth, whichever
occurred first. Randomization took place from April 9,
2001 to August 31, 2006.All children alive at 5 years of age underwent the
5-year assessment which included a neurologic assessment
to determine the presence of cerebral palsy and any
hearing/visual difficulties, and the completion of two parent
questionnaires. The 5-year study and all secondary analyses
were approved by the Research Ethics Board at the
Sunnybrook Health Sciences Centre. The institutions
were encouraged to contact the families of all surviving
children even if no contact had been made at 18–24
months of age for the 18–24 month follow-up assessment.
The target date for the visit was the child’s 5th birthday;
completing the assessments within 4 months of the target
date was encouraged but efforts to locate and assess the
children continued beyond this age when necessary.
Following ethics approval at each institution, written
informed consent was obtained from a parent or guardian.
The 5-year follow-up began in June 2006 and was
complete by May 2012.The primary outcome of the
5-year follow-up was a composite of death or survival
with a neurodevelopmental disability in at least one of the
following domains: neuromotor (non-ambulatory cerebral
palsy), neurosensory (blindness, deafness or a need for
visual or hearing aids), or neurocognitive/neurobehavioral
(abnormal attention, memory or behaviour) function.
Non-ambulatory cerebral palsy was present if the child
had a non-progressive motor impairment characterized
by abnormal muscle tone and decreased range of
movements, with a gross motor function of 3–5 as
defined in the Gross Motor Function Classification
System (GMFCS) [4]. Neurosensory disability was defined
as blindness, deafness, or need for visual or hearing aids
based on local criteria. Neurocognitive/neurobehavioral
disability was defined as an abnormally elevated score
(>1.5standard deviations above the normative control
sample) on either one of two parent-administered ques-
tionnaires: the Behavior Rating Inventory of Executive
Function- Preschool version (BRIEF-P) and the Child
Behavior Checklist-1½-5 (CBCL-1½-5) [5,6].
Analysis
The primary outcome and its components were analysed
using a general linear model for a binary response
(i.e. logistic regression) with repeated measures for
children from the same pregnancy. The model included
ACS treatment group (multiple, single), gestational age at
birth group (<30, 30–36, ≥37 weeks), plus its interaction
with ACS treatment group. The model included the
stratification variable gestational age at randomization
(26–27 vs. 28+ weeks) and, if the variables were
significant at the two-sided level of 0.1, the following
covariates from Table 1: preterm pre-labour rupture
of membranes (yes/no), multiple pregnancy (yes/no),
maternal smoking (yes/no), parity (0, 1+), sex of the
infant and the country’s perinatal mortality rate
Table 1 Characteristics at randomization into MACS by gestational age at delivery
Characteristic Preterm (<30 weeks)
N = 158 women
Preterm (30–36 weeks)
N = 781 women
Term (≥37 weeks)
N = 437 women
Mean maternal age (years) (SD) 29.3 (6.3) 29.8 (6.2) 28.1 (6.2)
Treatment group
Single course 76 (48.1%) 375 (48.0%) 236 (54.0%)
Repeat courses 82 (51.5%) 406 (52%) 201 (46.0%)
Multiple pregnancy 37 (23.4%) 244 (31.2%) 26 (5.9%)
Number of fetuses
Singleton 121 (77%) 537(69%) 411 (94%)
Twin 29 (18%) 197 (25%) 25 (6%)
Triplet 8 (5%) 47 (6%) 1 (<0.01%)
Mean gestational age at randomization (weeks) (SD) 27.2 (1.1) 29.7 (1.9) 29.6 (1.9)
Gestational age at randomization (weeks)
< 25 0 (0%) 0 (0%) 0 (0%)
25-27 114 (72%) 163 (21%) 91 (21%)
28-32 44 (28%) 618 (79%) 334 (79%)
> 32 0 (0%) 0 (0%) 2 (<0.01%)
Preterm pre-labor rupture of membranes at randomization 77 (49%) 138 (18%) 8 (1.8%)
National perinatal mortality rate of countryb
≤ 10/1000 127(80%) 553 (71%) 224 (51%)
> 10 - 20/1000 22 (14%) 187 (24%) 175 (40%)
> 20/1000 9 (6%) 41 (5%) 38 (9%)
Number of previous pregnancies
0 50 (32%) 245 (31%) 103 (24%)
1-4 91 (57%) 465 (60%) 287 (66%)
>4 17 (11%) 70 (9%) 45 (10%)
Missing 1 (<0.01%) 2 (<0.01%)
Maternal smoking 15 (9%) 64 (8%) 62 (14%)
Number of courses of study drug
0 2 (1.2%) 3 (<0.01%) 1 (<0.01%)
1 128(81%) 312 (40%) 109 (25%)
2 26 (16%) 225 (33%) 156 (36%)
3 1 (0.1%) 133 (17%) 103 (24%)
4 0 (0%) 78 (10%) 68 (16%)
Missing 1 (0.1%) 0 (0%) 0 (0%)
a1 child lost to follow-up case earlier in trial found and included at 5 years, no maternal data available.
bCountries with a national perinatal mortality rate of ≤10/1000 were: Canada, Chile, Denmark, Germany, Hungary, Israel, the Netherlands, Poland, Spain,
Switzerland, United Kingdom, United States; countries with a national perinatal mortality rate of >10 - 20/1000 were: Argentina, Brazil, Peru; countries with a
national perinatal mortality rate of >20/1000 were: Bolivia, China, Colombia, Jordan, Russia.
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very few neuromotor outcomes, the model would not
converge and no results for this component of the primary
outcome are given. Model estimation was facilitated by
generalized estimating equations, using PROC GENMOD
in SAS. Odds ratios plus 95% confidence intervals were
determined. This research adhered to the STROBE
guidelines for observational studies.Results
Study participants
Figure 1 illustrates the study group for MACS-5. For the
main 5-year follow-up, 413 children were unable to be
followed because they could not be located or parents
declined participation, 1 child lost for the neonatal and
2 year follow-up phase was found, leaving 1728 children
(80.7% of the 2141 eligible children) to contribute to the
1724 women eligible for MACS-5 
865 women allocated to 
multiple ACS group (1075 infants+ 
1 child found at 5 years=1076)
859 women allocated to 
single ACS group (1065 infants)







2 children with 
incomplete components 
of primary outcomes
871 children contributed to 
primary outcomes
7 children with 
incomplete components 
of primary outcomes
848 children contributed to 
primary outcomes
1858 women randomized in MACS



















105 children born < 30 
gestational weeks
553 children born 30-36 
gestational weeks
95children born < 30 
gestational weeks
504 children born 30-36 
gestational weeks
ACS = antenatal corticosteroid therapy
Figure 1 Study profile. This study profile outlines the recruitment of the children born preterm and term.
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insufficient information to contribute to the primary
outcome. In total, 1719 children contributed to the
primary outcome of MACS-5 and it is these children,
broken down into groupings of <30, 30–36, and ≥ 37 weeks
gestation at birth, who contribute to this secondary
analysis. The median age for the 5 year assessments
was 5.2 years.
The baseline maternal characteristics and co-
interventions after randomization are outlined in Table 1
by gestational ages at birth. A summary of the neo-
natal, 18–24 months and 5-year neurodevelopmental
outcomes of the study cohort are outlined in Table 2.
The baseline neonatal outcomes of the infants followed
compared to those not followed are outlined in the
Additional file 1: Table S1.
Outcome
The primary outcome and its components at 5 years of
age are given in Table 3 by ACS treatment groups andgestational age at birth. The covariate results for the
primary outcome and its components are given in
Table 4, and include the odds ratios, confidence intervals
and levels of significance. The odds ratios, confidence
limits and significance levels for the primary outcome and
its components are given by gestational age at birth
in Tables 5 and 6; the results were similar when the
covariates were omitted.
Gestational age at birth was strongly associated with
primary outcome as defined for 5 years of age, p <0.001.
The interaction between ACS group and gestational age at
birth was not significant, p =0.064 (Table 5). In the two
preterm groups, there was no difference seen in the
primary outcome or its components between ACS groups.
However, in children born at term, there was a statistically
significant increase in the risk of the primary outcome in
the multiple ACS group compared to the single ACS
group, 48/213 (22.5%) vs. 38/249 (15.3%); OR = 1.69 [95%
CI: 1.04, 2.77]; p = 0.037 (Table 5). In addition, there was a
significant interaction between ACS group and gestational
Table 2 Perinatal/neonatal, 18–24 months, and 5-year outcomes of infants/children by gestational age at delivery







Male 106 (53%) 560 (53%) 240 (52%)
Female 94 (47%) 506 (47%) 222 (48%)
Death or serious neonatal morbidity: composite primary outcome
(one or more of death, severe RDSc, BPDd, IVHe [grade III/IV],
cystic PVLf, NECg)
126 (64%) 107 (10%) 2 (<0.01%)
Missing 0 (0%) 0 (0%) 1 (<0.01%)
Death or neurologic impairment at 18–24 months: composite primary
outcome (one or more of death, cerebral palsy or cognitive delay)
89 (45%) 128 (12.0%) 27 (6%)
Missing 1 (0.01%) 5 (0.1%) 2 (<0.01%)
Death or severe disability (neuromotor, neurosensory,
neurocognitive) at 5 years §
104 (52%) 237 (22%) 86 (19%)
a1 lost to follow-up case earlier in trial found and included at 5 years; no neonatal and 18–24 months data available;
bNew information found on gender.
cRDS = respiratory distress syndrome; dBPD = bronchopulmonary dysplasia;
eIVH = intraventricular hemorrhage; fPVL = periventricular leukomalacia;
gNEC = necrotising enterocolitis.
§Clinical information of 19 cases missing/inadequate questionnaires were reviewed by an adjudication committee (10 cases were adjudicated to contribute to
analysis and primary outcome; 9 had insufficient information).
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the children born at term there was a significant increase
in the risk of neurosensory disability in the multiple ACS
group: 19/212 (9.0%) vs. 7/247 (2.8%); OR = 3.70 [95% CI:
1.57, 8.75]; p = 0.004. There was no interaction between
ACS group and gestational age at birth with respect to
neurocognitive/neurobehavioral disability or death.
Discussion
In this secondary analysis, we were able to demonstrate that







Death or severe disability (neuromotor,
neurosensory, neurocognitive)§
54/105 (51.4%) 50/95 (52.6%
Death up to 5 years 29/105 (27.6%) 23/95 (24.2%
Neuromotor disability †† (non-ambulatory
cerebral palsy)
1/76 (1.3%) 6/72 (8.3%)
Neurosensory disability 13/76 (17.1%) 13/72 (18.1%
Needing visual aids 9/76 (11.8%) 11/72 (15.3%
Deafness 4/76 (5.3%) 2/72 (2.8%)
Pre-existing (diagnosed at 2 years or earlier) 3 2
New (diagnosed after 2 years of age) 1 0
Neurocognitive/neurobehavioural disability 15/76 (19.7%) 16/69 (23.2%
ACS= antenatal corticosteroid.
a1 child lost to follow-up earlier in trial found and included at 5 years.
§Clinical information of 19 cases missing/inadequate questionnaires were reviewed
analysis and primary outcome; 9 had insufficient information).
††non-ambulatory cerebral palsy was defined as Gross Motor Function Classificationan adverse neurodevelopmental outcome regardless of the
number of courses of ACS. The earlier an infant was born,
the higher the chances of experiencing an adverse outcome.
In this study, half of the children who were born <30 weeks
gestation were presenting with at least one of the
components of the composite outcome. These figures
are consistent with many studies that show that the
more preterm infant continues to be at high-risk for
adverse outcomes and that these numbers have not
changed dramatically over the past decades [7-10].













) 115/553 (20.8%) 122/504 (24.2%) 48/213 (22.5%) 38/249 (15.3%)
) 16/555 (2.9%) 22/511 (4.3%) 1/213 (0.5%) 2/249 (0.8%)
3/539 (0.6%) 4/489 (0.8%) 0/212 (0%) 1/247 (0.4%)
) 38/539 (7.1%) 41/489 (8.4%) 19/212 (9.0%) 7/247 (2.8%)
) 35/539 (6.5%) 34/489 (7.0%) 17/212 (8.0%) 7/247 (2.8%)
4/539 (0.7%) 3/489 (0.6%) 3/212 (1.4%) 1/247 (0.4%)
1 2 0 0
3 1 3 1
) 62/534 (11.6%) 63/478 (13.2%) 31/212 (14.6%) 30/246 (12.2%)
by an adjudication committee (10 cases were adjudicated to contribute to
System III, IV or V.
Table 4 Covariates associated with neurodevelopmental outcomes at 5 years of age
Death or severe disability
Covariate Comparison OR [ 95% confidence limits] p-value
Gestational age at randomization 26-27 vs. 28+ weeks 1.02 [0.76, 1.38] 0.897
Premature rupture of membranes Yes vs. No 1.58 [1.14, 2.18] 0.009
Mother smokes Yes vs. No 1.62 [1.10, 2.40] 0.023
Parity 1+ vs. 0 1.26 [1.02, 1.56] 0.033
Country PMRa >10/1000 vs. ≤10/1000 1.33 [1.09, 1.61] 0.006
Neurosensory disability
Covariate Comparison OR [ 95% confidence limits] p-value
Gestational age at randomization 26-27 vs. 28+ weeks 1.04 [0.67, 1.60] 0.877
Premature rupture of membranes Yes vs. No 1.58 [0.94, 2.64] 0.110
Neurocognitive
Gestational age at randomization 26-27 vs. 28+ weeks 0.94 [0.64, 1.40] 0.764
Multiple pregnancy Yes vs. No 0.60 [0.41, 0.89] 0.006
Maternal smoking Yes vs. No 2.18 [1.44, 3.31] 0.002
Sex of the baby Male vs. Female 1.65 [1.23, 2.20] 0.001
Country PMRa >10/1000 vs. ≤10/1000 1.40 [1.10, 1.78] 0.012
Death
Gestational age at randomization 26-27 vs. 28+ weeks 1.42 [0.84, 2.40] 0.1984
Premature rupture of membranes Yes vs. No 2.08 [1.27, 3.41] 0.0089
parity 1+ vs. 0 1.44 [0.98, 2.11] 0.0700
Country PMRa >10/1000 vs. ≤10/1000 2.37 [1.69, 3.33] 0.0001
aPMR = perinatal mortality rate.
Countries with a national perinatal mortality rate of ≤10/1000 were: Canada, Chile, Denmark, Germany, Hungary, Israel, the Netherlands, Poland, Spain,
Switzerland, United Kingdom, United States; countries with a national perinatal mortality rate of >10 - 20/1000 were: Argentina, Brazil, Peru; countries with a
national perinatal mortality rate of >20/1000 were: Bolivia, China, Colombia, Jordan, Russia.
Asztalos et al. BMC Pregnancy and Childbirth 2014, 14:272 Page 6 of 8
http://www.biomedcentral.com/1471-2393/14/272found to still have a significant risk of an adverse
outcome but not as high as the more preterm group.
As with most interventions there are benefits but also
potential risks that must be balanced. MACS found
no improvement in preterm birth outcomes and
demonstrated a significant decrease in birth weight,
length and head circumference following administration
of multiple ACS, generating concern that there may be
potential for harm [1]. With the clinical diagnosis of
preterm labor being imprecise and interventions directed
to preventing or delaying preterm birth implemented, at
least a third of women can go on to give birth at
term [11]. Previous studies which have evaluated the
relationship of any effects of ACS on the infants are
often complicated by the fact that most of the infants
in these studies are preterm and are already at risk
for delayed growth and development.
In MACS, 32% of the women gave birth at term [1].
Infants born at term are unlikely to benefit from
multiple courses of ACS as they are not required for
pulmonary maturation. In the MACS cohort, less
than 1% of the infants born at term had any components
of the primary neonatal outcomes and less than 5% of the
adverse neurodevelopmental outcomes at 18–24 months[2]. Yet the children exposed to multiple courses of ACS
as fetuses and had gone on to be born at term had an
almost 4-fold increased odds of neurosensory difficulties
by 5 years of age. We also previously showed that this risk
of difficulties was not dose-dependent with ACS therapy
[3]. Although the absolute numbers for these impairments
are small, these differences may have important clinical
implications.
The term infant may be seen as one means of observing
specific effects of ACS as they, in general, are less at risk
for many of the growth and neurologic impairments often
seen in children born preterm [12,13]. More recently,
children born at term have been studied to evaluate the
potential long-term effects of ACS. Davis et al. noted that
fetal exposure to ACS had neurologic consequences that
persisted for at least 6 to 10 years as manifested by thinner
cortex measurements on MRI [12], with the regions most
affected being those involved with affective disorders
suggesting increased vulnerability to mental health issues.
Similarly, Alexander et al. showed that there were
long-lasting effects of ACS exposure on hypothalamic-
pituitary-adrenal reactivity in term-born children which
have implications regarding the vulnerability for health
and mental disorders [14].
Table 5 Adjusted odds ratios, confidence limits and p-values by gestational age at birth
Outcome Gestational age at birth OR [ 95% confidence limits] p-value p-value for interaction
Death or severe disabilitya < 30 weeks 0.85 [0.35, 2.11] 0.608 0.064
30-36 weeks 0.84 [0.52, 1.36] 0.262
≥ 37 weeks 1.69 [1.04, 2.77] 0.037*
Neurosensory disabilityb < 30 weeks 0.85 [0.35, 2.11] 0.732 0.021
30-36 weeks 0.84 [0.52, 1.36] 0.481
≥ 37 weeks 3.70 [1.57, 8.75] 0.004*
Neurocognitivec < 30 weeks 0.84 [0.35, 2.01] 0.698 0.605
30-36 weeks 0.91 [0.61, 1.36] 0.632
≥ 37 weeks 1.31 [0.75, 2.29] 0.347
Deathd < 30 weeks 1.10 [0.54, 2.24] 0.794 0.587
30-36 weeks 0.68 [0.35, 1.31] 0.247
≥ 37 weeks sparse data, no convergence
aadjusted for gestational age at randomization, premature rupture of membranes, maternal smoking, parity and the country’s perinatal mortality rate.
badjusted for gestational age at randomization and premature rupture of membranes.
cadjusted for gestational age at randomization, multiple pregnancy, maternal smoking, sex of the baby and the country’s perinatal mortality rate.
dadjusted for gestational age at randomization, premature rupture of membranes, parity and the country’s perinatal mortality rate.
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effects of multiple courses of ACS on critical nerves
within the central nervous system such as the optic and
auditory nerve [12-14]. Dunlop and Quinlivan examined
the effect of repeated injections of corticosteroids on the
development of the optic nerve and reported a disrupted
retinal development that persisited days after cessation of
treatment and a significant delay in the myelination of the
optic axons and thinning of the retina [15,16]. Church
et al. demonstrated that neonatal rats exhibited prolonged
auditory brainstem response latencies reflecting slower
neural transmission times along the auditory nerve and
brainstem auditory pathway, and associated hearing
deficits [17]. Similar effects may be present to account for
the differences seen in the term group of this study.
There are limitations to this secondary analysis, as the
groups based on gestational age at birth were definedTable 6 Unadjusted odds ratios by gestational age at birth
Outcome Gestational age at birth OR
Death or severe disability < 30 weeks 0.92
30-36 weeks 0.83
≥ 37 weeks 1.64
Neurosensory disability < 30 weeks 0.90
30-36 weeks 0.81
≥ 37 weeks 3.48
Neurocognitive < 30 weeks 0.76
30-36 weeks 0.90
≥ 37 weeks 1.30
Death < 30 weeks 1.19
30-36 weeks 0.66
≥ 37 weeks 0.58after randomization thus making it plausible that there
may have been pre-existing differences to account for
the findings. Notwithstanding, the strengths of the
study are that the data came from a large randomized
controlled trial and that greater than 80% of the cohort
has been followed. The neonatal outcomes of the children
who were followed and those who were not followed were
comparable reassuring us that there was a balance in the
gestational groups and that the numbers were not in-
appropriately inflated in one group more so than another.
Thus the results do present some concern about potential
long-term consequences of multiple ACS therapy which
clinicians need to consider especially if the benefits of
multiple ACS are not substantial.
Conclusions
In this secondary analysis, preterm birth was found to be
the primary factor contributing to an adverse neurodeve-
lopmental outcome regardless of the number of courses of
ACS. Children born ≥ 37 weeks and exposed to multiple
ACS therapy may have an increased risk of neurodevelop-
mental/neurosensory impairment. To optimize outcomes
for infants/children, efforts in reducing the incidence of
preterm birth should remain a primary focus in perinatal
research as the morbidities associated with preterm
birth continue to play an important role in the presence
of long-term outcomes. Future research should focus on
ensuring that ACS therapy be given at the most beneficial
time for the fetus to optimize its outcome in the event of
a preterm birth. Continued research is needed to answer
questions on the long-term effects of exposure to ACS
therapy, single and multiple, on later neurobehavioral
function, disabilities, mental disorders, and any suscepti-
bility to metabolic and cardiovascular disease.
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